BSX — Boston Scientific Corporation
Is BSX overbought or oversold? Here is the current MarketMoodz read.
Boston Scientific Corporation (BSX) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Devices) last closed at $43.03. The rating moved from Neutral to Oversold on November 17, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$43.03
- Last changeMoved from Neutral to Oversold on November 17, 2026
- SectorHealthcare
- IndustryMedical Devices
See all oversold Healthcare stocks →
AI analysis
Boston Scientific Corporation (BSX) is supported by a diversified device portfolio, a growing installed base that drives recurring consumable revenue, and an active product pipeline that should sustain mid-term top-line growth. Market conditions show measured risk-on tone with stable flows into large healthcare names, which should temper downside volatility. Near-term catalysts include continued procedure growth, product rollouts and adoption of surgical-robotics platforms that expand addressable markets. Key vulnerabilities include intensified competition in robotics and core device franchises, reimbursement/regulatory pressures that raise compliance costs, and sensitivity to hospital capital spending cycles. Social sentiment and recent filings are neutral, with no material surprises reported in the latest 8-K.
Key factors
- Diversified medtech portfolio spanning electrophysiology, peripheral interventions, endoscopy and structural heart increases revenue resilience
- Growing installed base and recurring consumable revenue provides predictable cash flow and margin support
- Surgical-robotics expansion of the addressable market benefits OEMs that capture OR adoption and consumable spend over time
- Recent sector flows into large-cap healthcare names and defensive allocations reduce downside volatility versus broader cyclicals
- Stable recent corporate filings (8-K neutral) with no material surprises in the immediate window
- Ongoing R&D and product launches support mid-term organic growth and competitive positioning
Risks
- Intense competition from large medtech peers and new entrants in surgical robotics and device categories could pressure market share and pricing
- Reimbursement and regulatory headwinds (including Medicare/Medicaid program integrity efforts) could increase compliance costs and indirectly affect procedure economics
- Hospital capital expenditure cycles and procedure volumes are sensitive to macro conditions, which can compress near-term device demand
- Supply chain disruptions or manufacturing issues could hit revenue and margins given reliance on complex components
- Litigation and product regulatory risks inherent to medical-device businesses could lead to unexpected costs or product restrictions
- Sector-specific developments (e.g., Medtronic Hugo RAS expansion) may accelerate competition for robotics-related consumables and OR adoption
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for BSX — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.